Effect of calcitonin on bone and connective tissue metabolism in hemiplegic patients: A two-year prospective study

Clinical Rehabilitation

Volumn 13, Issue 5, 1999, Pages 384-391

  Uebelhart, Daniel ^a,b,d   Hartmann, Daniel J ^c   Barbezat, Sylva ^a   Mermillod, Bernadette ^a   Chantraine, Alex ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITÉ LYON 1   (France)

^d University Hospital Beau Sejour   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN TYPE 1; OSTEOCALCIN; SALCATONIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METABOLISM; CALCIUM URINE LEVEL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; HEMIPLEGIA; HUMAN; INFORMED CONSENT; INTRANASAL DRUG ADMINISTRATION; MALE; OSSIFICATION; PROSPECTIVE STUDY; STROKE;

ADMINISTRATION, INTRANASAL; AGED; BONE AND BONES; BONE RESORPTION; CALCITONIN; CEREBROVASCULAR ACCIDENT; CONNECTIVE TISSUE; DOUBLE-BLIND METHOD; FEMALE; HEMIPLEGIA; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0032836264     PISSN: 02692155     EISSN: None     Source Type: Journal    
DOI: 10.1191/026921599672302142     Document Type: Article

References (43)

1. Peszczynski M. The fractured hip in hemiplegic patients. Geriatrics 1957; 12: 687-90.
2. Ramnemark A, Nyberg L, Borssén B, Olsson T, Gustafson Y. Fractures after stroke. Osteoporos Int 1998; 8: 92-95.
3. Takamoto S, Masuyama T, Nakajima M et al. Alterations of bone mineral density of the femurs in hemiplegia. Calcif Tissue Int 1995; 56: 259-62.
4. Del Puente A, Pappone N, Mandes MG, Mantova D, Scarpa R, Oriente P. Determinants of bone mineral density in immobilization: a study on hemiplegic patients. Osteoporos Int 1996; 6: 50-54.
5. Tanaka N, Sonoda S, Kondo K, Chino N. Reproducibility of dual-energy X-ray absorptiometry in the upper extremities in stroke patients. Disabil Rehabil 1997; 19: 523-27.
6. Mayo NE, Korner-Bitensky N, Becker R et al. Predicting falls among patients in a rehabilitation hospital. Am J Phys Med Rehabil 1989; 68: 139-46.
7. Nyberg L, Gustafson Y. Patients falls in stroke rehabilitation: a challenge to rehabilitation strategies. Stroke 1995; 26: 838-42.
8. Forster A, Young J. Incidence and consequences of falls due to stroke: a systematic inquiry. BMJ 1995; 311: 83-86.
9. Panin N, Gorday WJ, Paul BJ. Osteoporosis in hemiplegia. Stroke 1971; 2: 41-47.
10. Naftchi NE, Viau AT, Marshall CH, Davis S, Loman EW. Bone mineralisation in the distal forearm of hemiplegic patients. Arch Phys Med Rehabil 1975; 56: 487-92.
11. Prince RL, Price RI, Ho S. Forearm bone loss in hemiplegia: a model for the study of immobilization osteoporosis. J Bone Min Res 1988; 3: 305-10.
12. Singh A, Shah S, Kaplan P. Appendicular and spinal bone mineral content in early stroke. In: Dequeker J, Geusens P, Wahner HW eds. Bone mineral measurements by photon absorptiometry: methodological problems. Leuven: Leuven University Press, 1988: 344-46.
13. Iversen E, Hassager C, Christiansen C. The effect of hemiplegia on bone mass and soft tissue body composition. Acta Neurol Scand 1989; 79: 155-59.
14. Hamdy RC, Moore SW, Cancellaro VA, Harvill LM. Long-term effects of strokes on bone mass. Am J Phys Med Rehabil 1995; 74: 351-56.
15. Van Ouwenaller C, Uebelhart D, Chantraine A. Bone metabolism in hemiplegic patients. Scand J Rehabil Med 1989; 21: 165-70.
16. Copp DH, Cameron EC, Cheney BA, Davidson AGF, Henze KG. Evidence for calcitonin, a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962; 70: 638-49.
17. Chambers TJ, Magnus CJ. Calcitonin alters behaviour of isolated osteoclasts. J Pathol (Lond) 1982; 136: 27-39.
18. Van der Wiel HE, Lips P et al. Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover. J Bone Min Res 1993; 8: 1459-65.
19. Reginster JY, Denis D, Deroisy R et al. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Min Res 1994; 9: 69-73.
20. Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, Franchimont P. A 5-years controlled randomized study of prevention of postmenopausal trabecular bone loss with salmon calcitonin and calcium. Eur J Clin Invest 1994; 24: 565-69.
21. Barbezat S. Etude prospective randomisée et en double aveugle sur l'efficacité d'un traitement de calcitonine en spray nasal chez des hémiplégiques. MD thesis, Faculty of Medicine, University of Geneva, 1993.
22. Brixen K, Nielsen HK, Eriksen EF, Charles P, Mosekilde L. Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone Gla-protein. Calcif Tissue Int 1989; 44: 93-98.
23. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Min Res 1992; 7: 1389-98.
24. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328-32.
25. Risteli J, Elooma I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-40.
26. Kivirikko KI, Laitinen OI, Prockop DJ. Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 1967; 19: 249-55.
27. Risteli L, Risteli J. Non invasive methods for detection of organ fibrosis. In: Rojkind M ed. Connective tissue in health and disease. Volume 1. Boca Raton: CRC Press, 1989.
28. Katz IA, Epstein S. Post transplantation bone disease. J Bone Min Res 1992; 7: 123-26.
29. Uebelhart D, Hartmann D, Vuagnat H, Castanier M, Hachen HJ, Chantraine A. Early modifications of biochemical markers of bone metabolism in spinal cord injury patients: a preliminary study. Scand J Rehabil Med 1994; 26: 197-202.
30. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997; 7: 390-406.
31. Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 1983; 57: 819-24.
32. Abbiati G, Arrigoni M, Grignani S, Longoni A, Bartucci F, Castiglioni C. Effect of salmon calcitonin on deoxy-pyridinoline (Dpr) urinary excretion in healthy volunteers. Calcif Tissue Int 1994; 55: 346-48.
33. Kanis JA, Johnell O, Gullherg B et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992; 305: 1124-28.
34. Cardona JM, Pastor E. Calcitonin versus etidronate for the treatment of postamenopausal osteoporosis: a meta-analysis of published clinical trials. Osteopororis Int 1997; 7: 165-74.
35. Plosker GL, McTavish D. Intranasal salmon calcitonin: a review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 1996; 8: 378-400.
36. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994; 55: 82-86.
37. Munk Nielsen N, Von der Recke P, Hansen MA, Overgaard K, Christiansen C. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical markers. Calcif Tissue Int 1994; 55: 8-11.
38. Devogelaer JP, Azria M, Attinger M, Abbiati G, Castiglioni C, Nagant de Deuxchaisnes C. Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue. Calcif Tissue Int 1994; 55: 71-73.
39. Combe B, Cohen C, Aubin F. Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int 1997; 61: 10-15.
40. Ongphiphadhanakul B, Piaseu N, Chailurkit L, Rajatanavin R. Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover. Calcif Tissue Int 1998; 62: 379-82.
41. Reginster JY, Deroisy R, Lecart MP et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452-58.
42. Deftos LJ, Nolan JJ, Seely BL et al. Intrapulmonary drug delivery of salmon calcitonin. Calcif Tissue Int 1997; 61: 345-47.
43. Uebelhart D, Chantraine A, Demiaux-Domenech B. Use of biochemical markers to assess bone metabolism: a critical review for the rehabilitation medicine physician. J Rehabil Sci 1995; 8: 34-38.